Excited to see Destiny Breast 03 now published in NEJM! T-DXd is the current 2L standard of care for metastatic HER2+ breast cancer, and more to come from this agent in the future!
@OncoAlert #bcsm
Sara Tolaney
7,815 posts
Sara Tolaney
@stolaney1
Boston. MA
Joined December 2015
- Incredible review on ER+ disease by @DrHBurstein in NEJM-- with beautiful figures too! #bcsm @OncoAlert #NEJM @DanaFarber
- Breathtaking results from DB04 presented by Shaun Modi. Benefit for T-DXd irrespective of subtype & 1+/2+ IHC results A paradigm shift that breaks through traditional subgroup classification deserving of the standing ovation!!! #ASCO22 @OncoAlert
- DB-03: TDxd dramatically better than T-DM1 (HR 0.28)- complete responses in 16%! New 2L stnd of care. TDxd is revolutionizing outcomes for metastatic HER2+ dz Brilliant presentation by @JavierCortesMD
- KN522: Benefit of pembro seen regardless of stage or nodal status in early stage TNBC @OncoAlert #SABCS21
- RxPONDER: no benefit to chemo in postmenopausal pts 0-3 LNs RS 0-25; premenopausal pts benefited from chemo; 46% decrease in IDFS events; 53% decrease in deaths, 5-year OS absolute improvement of 1.3%; is this impact of suppression of ovarian fxn from chemo? #SABCS20 @OncoAlert
- Adjuvant olaparib x 1yr improves iDFS in pts with high risk breast cancer and gBRCAm! 👉3 yr iDFS 85.9% vs 77.1% (HR 0.58)-- absolute difference 8.8%. 👉Genetic testing should be offered to early stage pts @OncoAlert #bcsm
- Positive data for tesetaxel (oral taxane) in metastatic HR+ breast cancer announced! The CONTESSA trial Achieved its Primary Endpoint – Tesetaxel Plus a Reduced Dose of Capecitabine Significantly Improved PFS Versus Capecitabine Alone (Hazard Ratio=0.716; p=0.003; 9.8 vs 6.9 mo)
- Very big news out today-- adjuvant abemaciclib improves overall survival in high-risk ER+ breast cancer at ~7 yrs of f/u! Showing OS benefit in this setting is not easy & nice to see what an incredible impact adj cdk4/6i can have for our patients!
- monarchE: Results from cohort 1 (91% of pts were in cohort 1) HR 0.68 Benefit of adjuvant abemaciclib in high risk HR+ breast cancer seen @OncoAlert #ESMOBreast2022
- A lot is happening in breast cancer! ASCENT-04 reports improvement in PFS for sacituzumab + pembro vs TPC+pembro in 1L mTNBC, & DESTINY-Breast09 reports improved PFS for TDXd+P vs THP in 1L metastatic HER2+ breast cancer! Nice to see new options for our pts!
- Important study: DESTINY-Breast09 looking at TDXd +/- pertuzumab vs THP for 1L therapy of HER2+ MBC; currently enrolling
- TROPICS-02 Overall Survival data now published in The Lancet! Sacituzumab govitecan improved PFS, ORR, OS, & QOL c/w TPC in pts with pretreated metastatic HR+ BC. Benefit seen across all Trop-2 exp levels. @DFCI_BreastOnc @OncoAlert #bcsm sciencedirect.com/science/articl…
